Keyphrases
Glioblastoma
87%
Bevacizumab
75%
Nivolumab
50%
Recurrent Glioblastoma multiforme
39%
Cetuximab
37%
Irinotecan
37%
Recurrent Glioblastoma
37%
Overall Survival
36%
Positron Emission Tomography
26%
Epidermal Growth Factor Receptor
25%
Blood Volume
25%
Contrast Enhancement
23%
Glioblastoma multiforme
23%
18F-fluoroethyl-L-tyrosine (18F-FET)
22%
Clinical Trials
20%
Tumor Cells
20%
Tyrosine
18%
Magnetic Resonance Imaging
17%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
16%
PET-MRI
15%
Dynamic Contrast-enhanced
15%
Volume Images
15%
Radiation Therapy
15%
Phase II Study
15%
Cell State
15%
Primary Glioblastoma
14%
Lack of Response
14%
Patient Selection
14%
Prognostic Value
14%
Tumor
13%
Checkpoint Pathway
12%
Temsirolimus
12%
Temozolomide
12%
Glioma Cells
12%
Multimodal Strategy
12%
Glioma
12%
Angiogenic Growth Factors
12%
Targeted Therapy
12%
State Shift
12%
Prognostic Model
12%
Immune Response
12%
Molecular Profiling
12%
Phase II Trial
12%
F-18
12%
Combination Therapy
12%
Diagnostic Performance
12%
Anaplastic Astrocytoma
12%
Downstream Signaling
12%
Brain Lesions
12%
Perfusion Measurement
12%
Medicine and Dentistry
Glioblastoma
100%
Fluorine-18
50%
Neoplasm
42%
Magnetic Resonance Imaging
29%
Targeted Therapy
28%
Ganglioglioma
27%
Positron Emission Tomography
26%
Tyrosine
25%
Nivolumab
23%
Overall Survival
23%
Positron Emission Tomography - Magnetic Resonance Imaging
15%
Immunotherapy
14%
Hazard Ratio
13%
Neuro-Oncology
13%
Oligodendroglioma
12%
Nuclear Magnetic Resonance
12%
Diagnosis
12%
Cancer Treatment
12%
Mesenchymoma
12%
Positron Emission Tomography
12%
Drive
12%
Immune Response
12%
Bevacizumab
12%
Gene Expression Profiling
12%
Tumor Cell
11%
Diseases
9%
Macrophage
8%
Clinical Trial
8%
Intracranial Tumor
6%
Transcriptomics
6%
T Cell
5%